Ganli Pharmaceutical: The results of the phase Ib study of insulin weekly preparation GZR4 have been published in an international journal.

According to the news from Ganli Pharmaceutical, recently, the results of a Phase Ib clinical study of GZR4, a type 1 innovative insulin weekly formulation developed independently by Ganli Pharmaceutical, have been officially published in the endocrinology journal "Diabetes Research and Clinical Practice" in China. The article indicates that GZR4, when administered once a week to type 2 diabetes patients, showed good safety and tolerability after 6 weeks of treatment. Its pharmacokinetic and pharmacodynamic characteristics support its use as a basal insulin administered once a week, and the improvement in fasting blood sugar, glycosylated hemoglobin, glycosylated albumin, time within target blood sugar range, and other indicators in the various dose groups of GZR4 were superior to those of the detemir insulin group.